Cladribine Tablets Show Promising Results In Multiple Sclerosis Therapy
The cure for Multiple Sclerosis has once again been put to the spotlight as Merck KGaA, Darmstadt, Germany, a leading science and technology company, operating as EMD Serono in Canada has recently announced the findings obtained from their comprehensive study. The analysis has shown that Cladribine Tablets has demonstrated promising results as it has been found to have reduced the annualized rate of brain volume loss, which is usually referred to as brain atrophy, as compared with placebo in patients with relapsing remitting multiple sclerosis (RRMS). Experts said that the primary endpoint was the relapse rate of over 96 weeks; while the secondary endpoints were noted to have included MRI endpoints, proportion of subjects relapse-free, as well as disability progression at 96 weeks.
Cladribine Tablets In Multiple Sclerosis
Long before, Multiple sclerosis (MS) has been regarded as a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. According to reports revealed by CNW Online, experts have revealed that Cladribine Tablets is basically an investigational short-course oral therapy that selectively and periodically targets lymphocytes that are thought to be integral to the pathological process of MS. As of the press time, Cladribine Tablets is under clinical investigation and has not yet been approved for the treatment for any use in the United States, Canada and Europe.
The Study Involving Cladribine Tablets
Meanwhile, in one of her statements reported by MPR Online, study lead author and associate professor of neurology at the University of Siena, Nicola De Stefano said that the analysis obtained in the their study plays an important role because it confirms the link between reduced brain atrophy and reduced disability progression found in the study. The associate professor also said that the findings support the existing research which indicates that increased brain volume loss over time is associated with worse clinical outcomes, such as increased disability progression and cognitive changes, particularly in MS patients.
Furthermore, it was found that Cladribine Tablets are still in the process of being evaluated in a clinical development program and are yet to be approved for the treatment of any condition in the U.S. Additionally, with regards to the findings from the study, Merck CMO Steven Hildemann said that the findings will be able to make this investigational therapy available for patients living with relapse remitting multiple sclerosis.
HIV Progression Might Be Influenced By Genetics
As HIV has long been noted to be a communicable disease, what’s the truth behind the claims that the rate of speed of the virus’ progression may be influenced by the genetic component of the patient and the virus itself? If so, are there certain measures that a patient can do to slow down its progress? Here’s what health professionals have to say
Health Experts Alarmed About The Rise In STD Cases In South Carolina
Considering the ever growing cases of HIV/Aids all over the world, what's the truth behind claims that health experts have expressed their fear and concern over the rise in teen STD rate? Does this rise in number imply something significant? Here's what health professionals have to say
Congenital Muscular Dystrophy: Everything You Need To Know About The New Condition
Considering the fact that muscular dystrophy is a hereditary condition, how could our genetic component undergo the process of mutation? What’s the truth behind claims that because of this mutation, a new congenital muscular dystrophy has emerged? Is there still hope? Find out what experts have to say
Be Blessed By This Robot Priest In Germany
A robot priest named BlessU-2 beams lights from its hands and is giving 'auto-blessings' in the same German city where Martin Luther launched the Protestant Reformation.
Meet Elextra, Porsche Mission E And Tesla Model S' Biggest Rival
Elextra EV is being designed in Switzerland by Robert Palm, CEO of design house Classic Factory, but the project involves several other brands that are contributing in their respective areas of expertise.
The Controversial ‘Liberation Therapy’: Is It Good For Multiple Sclerosis?
With the number of advancements that has been intended for Multiple Sclerosis, why is the so-called ‘Liberation Therapy’ found to ineffective? What makes the said therapy to be considered as a failure when it comes to treating the auto-immune disease? Could it mean that it’s now a hopeless case for one of the world’s most dreaded diseases? Here’s what experts have to say
MORE IN ITECHPOST
Wellness Technology is a Billion Dollar Industry. Here Comes the Next Wave: Death Positive & Grief Wellness
The World Health Organization estimates that 25% of all people will be affected by mental or neurological disorders at some point in their lives, with roughly 450 million individuals currently struggling with a condition.
Find the build that’s right for you in the Metamorph League and experiment with other playstyles.
Defeat bosses in the Metamorph League and get tons of PoE currency like PoE orbs by knowing what the right build for you is in our Metamorph build guide!
Design Trends you Should Know
For everything from product labels to websites, the right design has a huge impact on people. Keeping up with the latest design styles is important because it lets organizations present a trendier and more modern vibe to their audience. Here are some of the biggest trends you can expect to see in the upcoming years.